Summit Therapeutics and AstraZeneca announced a $2 billion preferred convertible deal to advance new lung cancer treatments. The partnership also highlights expected fourth quarter squamous lung cancer data as a key near term catalyst.
published
Summit Therapeutics and AstraZeneca announced a $2 billion preferred convertible deal to advance new lung cancer treatments. The partnership also highlights expected fourth quarter squamous lung cancer data as a key near term catalyst.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.